NEW YORK, Aug. 29, 2023 /PRNewswire/ -- The autism spectrum disorder therapeutics market is set to grow by USD 772.65 million from 2022 to 2027, progressing at a CAGR of 7.2% during the forecast period. The rising prevalence of ASD drives the market growth during the forecast period. ASD is a serious illness that significantly impacts the communication and social interaction abilities as well as the behavior of those suffering from it. The disorder is classified as per several symptoms, which can differ from person to person. As per the Centers for Disease Control and Prevention (CDC), roughly one in every 54 children in the US has ASD, representing a ten-fold increase in the prevalence of ASD over the past four decades. As a result, there is an increase in investments in several R&D of new ASD medicines and therapies. Additionally, the growing awareness of this disease among people has led them to seek medical care and therapy options. Hence, such factors are positively impacting the market, which in turn will drive the market growth during the forecast period. Discover Pharmaceuticals industry potential and make informed business decisions based on qualitative and quantitative evidence highlighted in Technavio reports. View Sample Report!

Company Landscape

The autism spectrum disorder therapeutics market is fragmented and the companies are deploying organic and inorganic growth strategies to compete in the market. Some companies that are experts in the process industry are trying to increase their presence and market share by horizontally integrating with system integrators. End-users in discrete industries rely on their experiences from past purchases, based on which they maintain future relationships with companies. This enables global and established RPA companies to dominate local and regional companies in terms of quality, durability, reliability, and technological innovations. Hence, the competition among the companies in the global RPA market is expected to intensify during the forecast period.

• Bristol Myers Squibb Co: The company offers autism spectrum disorder therapeutics such as aripiprazole.
• CureMark LLC: The company offers autism spectrum disorder therapeutics such as CM AT therapy.
• F. Hoffmann La Roche Ltd: The company offers autism spectrum disorder therapeutics such as Balovaptan.

For the market's companies landscape highlights with a comprehensive list of companies and their offerings - View Sample in minutes

Autism Spectrum Disorder Therapeutics Market - Market Segmentation

This autism spectrum disorder therapeutics market report extensively covers market segmentation by distribution channel (retail pharmacy, hospital pharmacy, and online pharmacy), type (stimulants, selective serotonin reuptake inhibitors, antipsychotic drugs, sleep medications, and others), and geography (North America, Europe, Asia, and Rest of World). 

• The market share growth by the retail pharmacy segment is significant during the forecast period.

Autism Spectrum Disorder Therapeutics Market - Regional Market Outlook

North America is estimated to account for 39% of the market growth during the forecast period.

View Sample Report in minutes for more highlights into the market segments.

Companies Mentioned

• AutismSTEP
• Bristol Myers Squibb Co.
• CureMark LLC
• F. Hoffmann La Roche Ltd.
• Fraser
• Jazz Pharmaceuticals Plc
• Johnson and Johnson Services Inc.
• Les Laboratoires Servier SAS
• Neurim Pharmaceuticals Ltd.
• Novartis AG
• Oryzon Genomics SA
• Otsuka Holdings Co. Ltd.
• PaxMedica Inc.
• Q BioMed Inc.
• Scioto Biosciences Inc.
• Spectrum Pharmaceuticals Inc.
• Stalicla SA
• Travere Therapeutics Inc.
• Yamo Pharmaceuticals LLC
• Zynerba Pharmaceuticals Inc.

What's New? 

• Special coverage on the Russia-Ukraine war; global inflation; recovery analysis from COVID-19; supply chain disruptions, global trade tensions; and risk of recession 
• Global competitiveness and key competitor positions
• Market presence across multiple geographical footprints - Strong/Active/Niche/Trivial - buy the report! 

Autism Spectrum Disorder Therapeutics Market - Market Dynamics

Key Trend

The rising interest in personalized medicine for the treatment of ASD is a primary trend in the market during the forecast period. There is a growing popularity for personalized medical procedures for the treatment of ASD. Personalized medicine can be referred to as the practice of personalized medical treatments to individual patients depending on their genetic, environmental, and lifestyle characteristics. The main objective of personalized treatment is to offer a more accurate and effective treatment with few severe effects. As ASD is a complex illness that differs from person to person, standard treatment methods that work for all patients are not effective. Hence, it is expected to fuel the demand for personalized medicine which in turn will drive the market growth during the forecast period.

Significant Challenge - Stringent regulations on ASD therapeutics and treatments are a major challenge hindering the market growth during the forecast period. 

Gain instant access to 17,000+ market research reports. 

Technavio's SUBSCRIPTION platform

Related Reports:

The penicillin market size is estimated to grow by USD 2,450.23 million at a CAGR of 4.98% between 2022 and 2027. The market is segmented into Type (oral and parenteral), Source(semisynthetic and natural), and Geography(North America, Europe, Asia, and the Rest of the World (ROW)). The rising prevalence of infectious diseases is the key driver for the growth of the market. 

The cell culture media and reagents market size is estimated to grow by USD 4,810.25 million at a CAGR of 8.14% between 2022 and 2027. The market is segmented into End-user(pharmaceutical and biotechnology industry, academic institutions and research laboratories, and others), Product(media and reagents), and Geography (North America, APAC, Europe, and the Rest of the World (ROW)).

Table of Contents

1 Executive Summary

2 Market Landscape

3 Market Sizing

4 Historic Market Size

5 Five Forces Analysis

6 Market Segmentation by Distribution Channel

7 Market Segmentation by Type

8 Customer Landscape

9 Geographic Landscape

10 Drivers, Challenges, and Trends

11 Company Landscape

12 Company Analysis

13 Appendix

About Us
Technavio is a leading global technology research and advisory company. Their research and analysis focus on emerging market trends and provide actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions. With over 500 specialized analysts, Technavio's report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio's comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.

Contact
Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
Email: media@technavio.com
Website: www.technavio.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/autism-spectrum-disorder-therapeutics-market-to-grow-by-usd-772-65-million-from-2022-to-2027--increasing-prevalence-of-asd-boosts-the-market-growth---technavio-301911478.html

SOURCE Technavio